VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
About 1% to 2% of NSCLCs have the ROS1 mutation. The ROS1 mutation is similar to the ALK mutation. Some of the same drugs help treat both mutations. Targeted therapies for ROS1-positive lung ...
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer. Ensacove (ensartinib) has been approved by the Food and Drug ...
a novel ROS1-selective inhibitor, and ALKOVE-1 Phase 1/2 clinical trial of NVL-655, a novel ALK-selective inhibitor, during two oral presentations at the Eu Nuvalent, Inc. (Nasdaq: NUVL), a ...
The European Commission (EC) has approved sugemalimab (brand name: Cejemly ®) in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback